According to filings with the U.S. Securities and Exchange Commission, VST Bio Corp is raising up to $28,888,146.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About VST Bio Corp
VST-Bios team envisions a future where ischemic stroke and myocardial infraction no longer impose a life-threatening tissue damage or progression to neurological dysfunction or heart failure. Today, the efficacy of potential therapy for these acute diseases is determined by the delay in presentation at a medical center after onset of symptoms. Frequently, medical therapy is not effective anymore when presented 4-6 hours after onset of symptoms, and only prophylactic medication is given to prevent a possible second harmful event. Our VST-Bio humanized antibody, delivered via a simple IV bolus infusion, reverses vascular dysfunction and selectively regulates vascular permeability. Vascular leakage is a co-morbidity seen in a variety of diseases including stroke, myocardial infarction, traumatic brain injury, reperfusion injury, ARDS/ COVID-19 infection, oncology, and shock. Vascular leakage leads to edema formation, inflammatory infiltration, and reperfusion injury due to oxidative stress, and leads to aggravation of cerebral damage following stroke.

To learn more about VST Bio Corp, visit https://www.vst-bio.com/
VST Bio Corp Linkedin Page: https://www.linkedin.com/search/results/companies/?keywords=VST%20Bio%20Corp

Contact:
Krisztina Zsebo, Chief Executive Officer
858-663-8641

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.